SG/CALL/TEVA PHARMACEUTICAL INDUSTRIES/10/1/20.09.24 Stock

Warrant

DE000SQ3G7X0

Market Closed - Deutsche Boerse AG 15:48:40 2024-06-21 EDT
6.63 EUR -2.21% Intraday chart for SG/CALL/TEVA PHARMACEUTICAL INDUSTRIES/10/1/20.09.24
Current month+2.16%
1 month+4.74%
Date Price Change
24-06-21 6.63 -2.21%
24-06-20 6.78 +5.61%
24-06-19 6.42 -4.04%
24-06-18 6.69 -2.48%
24-06-17 6.86 +0.88%

Delayed Quote Deutsche Boerse AG

Last update June 21, 2024 at 03:48 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying TEVA PHARMACEUTICAL INDUSTRIES LIMITED
IssuerLogo Issuer Société Générale Société Générale
WKN SQ3G7X
ISINDE000SQ3G7X0
Date issued 2022-10-27
Strike 10 $
Maturity 2024-09-20 (89 Days)
Parity 1 : 1
Emission price 2.29
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 7.22
Lowest since issue 0.85
Delta0.96x
Omega 2.261
Premium1.43x
Gearing2.35x
Moneyness 1.696
Difference Strike -6.96 $
Difference Strike %-69.60%
Spread 0.07
Spread %1.03%
Intrinsic value 6.508

Company Profile

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
-
More about the company

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Teva Pharmaceutical Industries Limited

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
16.96 USD
Average target price
18.34 USD
Spread / Average Target
+8.11%
Consensus